Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results
August 05, 2021 08:30 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
June 04, 2021 08:00 ET
|
Purple Biotech Ltd.
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 07:38 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
May 20, 2021 07:00 ET
|
Purple Biotech Ltd.
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted REHOVOT, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- ...
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
May 19, 2021 07:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
April 23, 2021 08:00 ET
|
Purple Biotech Ltd.
Preliminary Data from First Part of Study Anticipated in Second Half of 2021 REHOVOT, Israel, April 23, 2021 (GLOBE NEWSWIRE) -- Purple Biotech (Nasdaq/TASE: PPBT), a clinical-stage company...
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
April 13, 2021 08:17 ET
|
Purple Biotech Ltd.
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers
March 19, 2021 08:00 ET
|
Purple Biotech Ltd.
Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb Preliminary Data from First Part of Study Expected to be Available in Second Half of 2021 REHOVOT, Israel, March 19,...
Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
March 11, 2021 08:02 ET
|
Purple Biotech Ltd.
TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
March 03, 2021 07:00 ET
|
Purple Biotech Ltd.
Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies...